Ebastine

Drug Profile

Ebastine

Alternative Names: Bactil; Bromselon; Ebastel; Evastel; Kestine; LAS 90DS; LAS W-090; LAS-90; Rinobactil; RP 64305; W-090

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Almirall-Prodesfarma
  • Developer Almirall S.A.; Meiji Seika Pharma; Sanofi; sanofi-aventis; Sumitomo Dainippon Pharma
  • Class Antiallergics; Biphenyl compounds; Butyrophenones; Piperidines; Small molecules
  • Mechanism of Action Histamine H1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Allergic conjunctivitis; Allergic rhinitis; Urticaria

Most Recent Events

  • 19 Jun 2014 Dainippon Sumitomo Pharma is now called Sumitomo Dainippon Pharma
  • 27 Mar 2012 Nycomed is now called Takeda Pharmaceuticals International GmbH
  • 30 Sep 2011 Nycomed has been acquired by Takeda
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top